Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Leukemia & lymphoma·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Detection and classification of lymphoma from cell-free methylome data.

NPJ precision oncology·2026
Same author

Targeted therapy in early-stage classical Hodgkin lymphoma.

Blood·2026
Same author

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Haematologica·2026
Same author

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology·2026

Related Experiment Video

Updated: May 9, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Relapsed and refractory aggressive NHL: time for a change.

Shane Gangatharan1, John Kuruvilla

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Canada.

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|July 10, 2013
PubMed
Summary

Outcomes for aggressive non-Hodgkin lymphoma (NHL) patients relapsing after initial treatment are poor. New therapies are needed as standard treatments like autologous stem cell transplantation (ASCT) are not suitable for most patients.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Aggressive non-Hodgkin lymphoma (NHL) presents significant treatment challenges, particularly in relapsed or refractory cases.
  • Current salvage chemotherapy followed by autologous stem cell transplantation (ASCT) offers cure for some but is not a viable option for many patients.

Purpose of the Study:

  • To review established treatment standards for relapsed or refractory B- and T-cell NHL.
  • To identify emerging therapeutic strategies and areas for future research in NHL management.

Main Methods:

  • Literature review of standard treatment protocols for aggressive NHL.
  • Analysis of recent advancements in NHL biology and novel therapeutic approaches.

Main Results:

  • The efficacy of salvage chemotherapy and ASCT is limited, with a significant portion of patients being ineligible.
  • Advances in understanding NHL pathogenesis are paving the way for novel treatment options.

Conclusions:

  • There is a critical need for improved treatment strategies for patients with relapsed or refractory aggressive NHL.
  • Further investigation into novel therapies is warranted to address the unmet needs in this patient population.